About Edge Therapeutics (NASDAQ:EDGE)
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company's initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company's product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company's product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$2.02 per share
Price / Book8.17
Return on Equity-67.83%
Return on Assets-50.02%
Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions
What is Edge Therapeutics' stock symbol?
Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."
How were Edge Therapeutics' earnings last quarter?
Edge Therapeutics Inc (NASDAQ:EDGE) posted its quarterly earnings data on Thursday, March, 1st. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.02. View Edge Therapeutics' Earnings History.
When will Edge Therapeutics make its next earnings announcement?
Where is Edge Therapeutics' stock going? Where will Edge Therapeutics' stock price be in 2018?
1 brokers have issued twelve-month target prices for Edge Therapeutics' stock. Their forecasts range from $17.00 to $17.00. On average, they expect Edge Therapeutics' stock price to reach $17.00 in the next year. View Analyst Ratings for Edge Therapeutics.
Who are some of Edge Therapeutics' key competitors?
Some companies that are related to Edge Therapeutics include Biohaven Pharmaceutical (BHVN), Intellia Therapeutics (NTLA), Retrophin (RTRX), Amarin (AMRN), Alder Biopharmaceuticals (ALDR), Mirati Therapeutics (MRTX), Amphastar Pharmaceuticals (AMPH), Regenxbio (RGNX), Lexicon Pharmaceuticals (LXRX), Collegium Pharmaceutical (COLL), Flexion Therapeutics (FLXN), Jounce Therapeutics (JNCE), Vanda Pharmaceuticals (VNDA), Pharming Group (PHGUF), MiMedx Group (MDXG), CymaBay Therapeutics (CBAY), Anika Therapeutics (ANIK) and ProMetic Life Sciences (PFSCF).
Who are Edge Therapeutics' key executives?
Edge Therapeutics' management team includes the folowing people:
- Sol J. Barer Ph.D., Independent Chairman of the Board (Age 69)
- Brian A. Leuthner, President, Chief Executive Officer, Director (Age 52)
- Isaac Blech, Independent Vice Chairman of the Board
- Andrew Saik, Chief Financial Officer (Age 48)
- Daniel Brennan, Chief Operating Officer (Age 49)
- W. Bradford Middlekauff, Senior Vice President, General Counsel, Secretary (Age 55)
- Alyssa J. S. Wyant, Senior Vice President, Regulatory Affairs (Age 42)
- Albert N. Marchio II, Chief Accounting Officer, Chief Administrative Officer (Age 64)
- R. Loch Macdonald M.D. Ph.D., Chief Scientific Officer, Director (Age 55)
- Herbert J. Faleck, Chief Medical Officer (Age 64)
Has Edge Therapeutics been receiving favorable news coverage?
Headlines about EDGE stock have been trending positive on Wednesday, according to Accern. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Edge Therapeutics earned a news impact score of 0.39 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Edge Therapeutics' major shareholders?
Edge Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include VHCP Management II LLC (3.16%), BlackRock Inc. (3.06%), Eagle Asset Management Inc. (2.86%), Millennium Management LLC (0.90%), Regentatlantic Capital LLC (0.29%) and Schwab Charles Investment Management Inc. (0.29%). Company insiders that own Edge Therapeutics stock include Albert N Marchio II, Brian A Leuthner, James J Loughlin, R Loch Macdonald and W Bradford Middlekauff. View Institutional Ownership Trends for Edge Therapeutics.
Which institutional investors are selling Edge Therapeutics stock?
EDGE stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Millennium Management LLC and Regentatlantic Capital LLC. Company insiders that have sold Edge Therapeutics company stock in the last year include Albert N Marchio II, Brian A Leuthner and R Loch Macdonald. View Insider Buying and Selling for Edge Therapeutics.
Which institutional investors are buying Edge Therapeutics stock?
EDGE stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Granite Investment Partners LLC, BlackRock Inc., SG Americas Securities LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Edge Therapeutics stock in the last two years include James J Loughlin and W Bradford Middlekauff. View Insider Buying and Selling for Edge Therapeutics.
How do I buy shares of Edge Therapeutics?
Shares of EDGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Edge Therapeutics' stock price today?
One share of EDGE stock can currently be purchased for approximately $16.51.
How big of a company is Edge Therapeutics?
Edge Therapeutics has a market capitalization of $512.43 million. The biotechnology company earns $-50,850,000.00 in net income (profit) each year or ($1.68) on an earnings per share basis. Edge Therapeutics employs 38 workers across the globe.
How can I contact Edge Therapeutics?
Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected]
MarketBeat Community Rating for Edge Therapeutics (EDGE)MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Edge Therapeutics (NASDAQ:EDGE) Earnings History and Estimates Chart
Edge Therapeutics (NASDAQ EDGE) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Edge Therapeutics (NASDAQ:EDGE) Earnings Estimates
2018 EPS Consensus Estimate: ($2.10)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Edge Therapeutics (NASDAQ:EDGE)
No dividend announcements for this company have been tracked by MarketBeat.com
Edge Therapeutics (NASDAQ EDGE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 36.19%
Institutional Ownership Percentage: 48.89%
Edge Therapeutics (NASDAQ EDGE) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/1/2018||Brian A Leuthner||CEO||Sell||2,500||$14.81||$37,025.00||72,736|| |
|2/22/2018||R. Loch Macdonald||Insider||Sell||2,500||$14.49||$36,225.00||590,602|| |
|2/20/2018||R. Loch Macdonald||Insider||Sell||5,000||$13.75||$68,750.00||590,602|| |
|2/1/2018||Brian A Leuthner||CEO||Sell||2,500||$13.14||$32,850.00||82,736|| |
|1/3/2018||Brian A Leuthner||Insider||Sell||5,000||$10.11||$50,550.00||87,736|| |
|12/5/2017||Brian A Leuthner||Insider||Sell||7,500||$9.86||$73,950.00||95,236|| |
|12/1/2017||Brian A Leuthner||CEO||Sell||2,500||$9.92||$24,800.00||95,236|| |
|11/22/2017||Albert N. Marchio II||Insider||Sell||3,361||$10.00||$33,610.00|| |
|11/3/2017||Brian A Leuthner||Insider||Sell||7,500||$10.91||$81,825.00||102,736|| |
|11/1/2017||Brian A Leuthner||CEO||Sell||2,500||$10.92||$27,300.00||102,736|| |
|10/4/2017||Brian A Leuthner||Insider||Sell||7,500||$10.96||$82,200.00|| |
|10/3/2017||Brian A Leuthner||CEO||Sell||2,500||$10.93||$27,325.00||110,236|| |
|10/2/2017||Brian A Leuthner||CEO||Sell||2,500||$10.81||$27,025.00||110,236|| |
|9/6/2017||Brian A Leuthner||Insider||Sell||7,500||$10.21||$76,575.00||117,736|| |
|9/5/2017||Brian A Leuthner||CEO||Sell||2,500||$9.94||$24,850.00||117,736|| |
|9/1/2017||Brian A Leuthner||CEO||Sell||2,500||$10.37||$25,925.00||117,736|| |
|8/29/2017||Albert N Marchio II||Insider||Sell||2,500||$10.42||$26,050.00||3,361|| |
|8/23/2017||Albert N Marchio II||Insider||Sell||1,000||$10.39||$10,390.00||5,861|| |
|8/3/2017||Brian A Leuthner||Insider||Sell||7,500||$10.53||$78,975.00||125,236|| |
|7/6/2017||Brian A Leuthner||Insider||Sell||7,500||$10.19||$76,425.00||132,736|| |
|3/6/2017||James J Loughlin||Director||Buy||3,000||$9.24||$27,720.00||19,625|| |
|2/7/2017||Brian A Leuthner||Insider||Sell||1,500||$9.52||$14,280.00||245,479|| |
|2/6/2017||Brian A Leuthner||Insider||Sell||3,000||$9.61||$28,830.00||248,479|| |
|2/2/2017||Brian A Leuthner||Insider||Sell||3,000||$9.50||$28,500.00||251,479|| |
|12/1/2016||Brian A Leuthner||Insider||Sell||7,500||$11.60||$87,000.00||252,979|| |
|10/3/2016||Brian A Leuthner||Insider||Sell||7,500||$10.25||$76,875.00||260,479|| |
|8/8/2016||W Bradford Middlekauff||VP||Buy||10,000||$9.48||$94,800.00||9,857|| |
|8/1/2016||Brian A Leuthner||Insider||Sell||7,500||$9.54||$71,550.00||267,979|| |
|3/11/2016||James Healy||Director||Buy||541,343||$7.30||$3,951,803.90|| |
|10/6/2015||Andrew J. Einhorn||CFO||Buy||45,000||$11.00||$495,000.00||41,656|| |
|10/6/2015||James Healy||Director||Buy||450,000||$11.00||$4,950,000.00|| |
Edge Therapeutics (NASDAQ EDGE) News Headlines
Edge Therapeutics (NASDAQ:EDGE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Edge Therapeutics (NASDAQ:EDGE) Income Statement, Balance Sheet and Cash Flow Statement
Edge Therapeutics (NASDAQ EDGE) Stock Chart for Wednesday, March, 21, 2018